Ki67 a Potential Prognostic Biomarker in Triple Negative Breast Cancer

Naveen Dhingra*
Department of Biotechnology, Sanghvi Institute of Management and Science, Indore (MP), India

*Corresponding Author: Naveen Dhingra, Department of Biotechnology, Sanghvi Institute of Management and Science, Indore (MP), India.

Received: November 23, 2017; Published: January 08, 2018

Triple negative breast cancer (TNBC) is an aggressive subgroup of breast cancer, which lacks effective target therapy. There have been numbers of biomarkers in TNBC, but it was reported that the level of Ki67 is 80% in ductal TNBC in comparison to other cancers [1]. The Ki67 antigen is a nuclear protein expressed in the G1, S, G2 and M phase of the cell cycle, but not in resting cells in G0. Therefore, the nuclear expression of Ki67 can be evaluated to assess tumor proliferation. High expression of Ki67 also represents a direct correlation to tumour size and an increased rate of death in TNBC patients [2-4].

There is very important role of expression of Ki67 and chemotherapy resistant/susceptible patients. On the basis of this the expression of chemotherapy in TNBC makes three groups of tumor [4]:

1. High Ki67 linked to poor outcome, when high proliferating tumors are therapy resistant.
2. In contrast, high Ki67 of linked to good outcomes, when high proliferating tumors are therapy sensitive.
3. Low expression of Ki67 linked to good outcomes, when low proliferating tumors are not responding to chemotherapy.

In conclusion, it might be stated that the level of Ki67 may be considered as a valuable biomarker and it might stratify TNBC into subtype with different aggressiveness and prognosis.

Bibliography